...
首页> 外文期刊>Romanian Journal of Diabetes Nutrition and Metabolic Diseases >Efficacy of Epalrestat, Duloxetine and Epalrestat in Combination with Methylcobalamine in Diabetic Peripheral Neuropathy
【24h】

Efficacy of Epalrestat, Duloxetine and Epalrestat in Combination with Methylcobalamine in Diabetic Peripheral Neuropathy

机译:依帕司他,度洛西汀和依帕司他联合甲基钴胺素在糖尿病周围神经病变中的疗效

获取原文
           

摘要

Diabetic neuropathy is a major long term problem allied with diabetes that can cause serious disability and also death. Fifty to seventy five percent of all ulcerations and non trauma amputations are a consequence of diabetic neuropathy. Epalrestat, duloxetine and epalrestat with methylcobalamine are widely used to overcome neuronal damage. This study was designed to evaluate the efficacy of these three drug regimens. Material and methods: Patients included in this study were experiencing pain because of diabetic neuropathy for more than 6 months but not more than 5 years. Results: From 236 subjects with diabetic neuropathy included in the study, 181 patients concluded final analysis. 55 patients dropped from the study (14, 23 and 18 patients from duloxetine, epalrestat+methylcobalamine combination and epalrestat respectively). Mean pain score was reduced from 5.01±1.99 (severe pain) at first visit to 2.86±2.10 (moderate pain) in the epalrestat group, from 6.41±1.73 (severe pain) at first visit to 2.38±1.58 (mild pain) in the duloxetine group and from 5.86±1.76 (severe pain) to 2.88±1.91 (mild pain) in the epalrestat with methylcobalamine group. Conclusion: We conclude that duloxetine was significantly more effective than epalrestat and epalrestat in combination with methylcobalamine in relieving diabetic neuropathic pain.
机译:糖尿病性神经病是与糖尿病有关的主要长期问题,可导致严重的残疾甚至死亡。在所有溃疡和非创伤性截肢中,百分之五到百分之七十五是糖尿病性神经病的结果。 Epalrestat,度洛西汀和epalrestat与甲基钴胺素被广泛用于克服神经元损伤。本研究旨在评估这三种药物方案的疗效。材料和方法:纳入本研究的患者由于糖尿病性神经病变而经历疼痛超过6个月但不超过5年。结果:从纳入研究的236位糖尿病性神经病变患者中,有181例患者完成了最终分析。 55名患者退出研究(分别来自度洛西汀,依帕司他+甲基钴胺素和依帕司他的14、23和18例患者)。依帕司他组的平均疼痛评分从首次就诊时的5.01±1.99(重度疼痛)降低至2.86±2.10(中度疼痛),从首次就诊时的6.41±1.73(重度疼痛)降低至2.38±1.58(轻度疼痛)。度洛西汀组和依帕曲他联合甲基钴胺治疗组从5.86±1.76(严重疼痛)至2.88±1.91(轻度疼痛)。结论:我们得出的结论是,度洛西汀在缓解糖尿病性神经性疼痛方面比依帕司他和依帕司他联合甲基甲钴胺有效得多。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号